TOP > 外国特許検索 > Heparin-binding protein modified with heparan sulfate sugar chains, process for producing the same and pharmaceutical compositions containing the same

Heparin-binding protein modified with heparan sulfate sugar chains, process for producing the same and pharmaceutical compositions containing the same コモンズ

外国特許コード F130007236
整理番号 2006003228
掲載日 2013年3月27日
出願国 アメリカ合衆国
出願番号 54734605
公報番号 20080119403
公報番号 7741078
出願日 平成17年3月31日(2005.3.31)
公報発行日 平成20年5月22日(2008.5.22)
公報発行日 平成22年6月22日(2010.6.22)
国際出願番号 JP2005006364
国際公開番号 WO2005095600
国際出願日 平成17年3月31日(2005.3.31)
国際公開日 平成17年10月13日(2005.10.13)
優先権データ
  • 特願2004-108570 (2004.3.31) JP
  • 2005WO-JP06364 (2005.3.31) WO
発明の名称 (英語) Heparin-binding protein modified with heparan sulfate sugar chains, process for producing the same and pharmaceutical compositions containing the same コモンズ
発明の概要(英語) (US7741078)
A heparin-binding protein having covalently bonded heparan sulfate sugar chains within its molecule is produced by ligating a cDNA encoding a peptide which can be modified with heparan sulfate sugar chains selectively to a cDNA encoding a heparin-binding protein and producing in an animal cell the gene product of the resultant ligated cDNA.
This heparan sulfate sugar chain-modified heparin-binding protein is functionalized by covalently bonding thereto glycosaminoglycan sugar chains containing little chondroitin sulfate.
For example, this heparin-binding protein is excellent in stabilities, such as thermostability, acid resistance, alkali resistance and in vivo stability.
Further, the heparan sulfate sugar chain-modified heparin-binding protein is effective in cell proliferation and tissue regeneration, and has effect of regulating the physiological functions of FGFs.
Thus, this heparin-binding protein is extremely useful as a medicine for preventing or treating various FGF-related diseases.
特許請求の範囲(英語) [claim1]
1. A method of producing a heparin-binding protein having at least one sulfated glycosaminoglycan sugar chain covalently bonded thereto, wherein 90% or more of said at least one sulfated glycosaminoglycan sugar chain being a heparan sulfate sugar chain, wherein the method comprises: (a) a step of ligating a cDNA encoding a peptide consisting of an amino acid sequence shown in SEQ ID NO: 8 which is capable of being modified with at least one heparan sulfate sugar chain to a cDNA encoding a heparin-binding protein;
(b) a step of incorporating the resultant ligated cDNA into an expression vector;
(c) a step of introducing the expression vector into a host cell having a pathway for heparan sulfate sugar chain biosynthesis; and
(d) a step of expressing in the host cell a heparin-binding protein to which at least one heparan sulfate sugar chain is covalently bonded through the peptide consisting of the amino acid sequence shown in SEQ ID NO: 8.
[claim2]
2. The method of claim 1, wherein the cDNA encoding the peptide consists of a nucleotide sequence as shown in SEQ ID NO: 13.
[claim3]
3. The method of claim 1, wherein the heparin-binding protein is a compound belonging to the fibroblast growth factor family.
[claim4]
4. A nucleic acid consisting of the nucleotide sequence as shown in SEQ ID NO: 13 and encoding a peptide which is capable of being modified with at least one heparan sulfate sugar chain.
  • 発明者/出願人(英語)
  • IMAMURA TORU
  • ASADA MASAHIRO
  • SUZUKI MASASHI
  • NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
国際特許分類(IPC)
米国特許分類/主・副
  • C07K014/50A
  • K61K038/00
  • M07K319/35

PAGE TOP

close
close
close
close
close
close